Global Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 – ResearchAndMarkets.com

The global adult vaccine market is expected to witness substantial growth, reaching a projected value of US$ 27.65 Billion by 2028, with a strong compound annual growth rate (CAGR) of 6.01% during 2022-2028. Vaccines play a crucial role in global…

Read MoreGlobal Adult Vaccine Market Projected to Reach $27.65 Billion by 2028 with a Strong CAGR of 6.01% During 2023-2028 – ResearchAndMarkets.com

Shapeways Secures Multi-Million-Dollar Medical ContractsRealizing a 3X growth within its medical base in the past 4 years

Shapeways, Inc. (NYSE: SHPW), a global leader in the digital manufacturing industry, announced today the expansion of its medical customer base within its Enterprise Manufacturing Solutions business by securing two significant contracts. These strategic partnerships should generate revenue of approximately $2.5…

Read MoreShapeways Secures Multi-Million-Dollar Medical ContractsRealizing a 3X growth within its medical base in the past 4 years

Impetus Grants Secures $10 million Commitment from Hevolution Foundation and Rosenkranz Foundation to Fund Aging Science

Impetus Grants, a nonprofit foundation dedicated to funding aging-related research that might otherwise be overlooked by traditional funding sources, announces a new round of matching funding. Hevolution Foundation, a global non-profit organization that provides grants and early-stage investments to incentivize research…

Read MoreImpetus Grants Secures $10 million Commitment from Hevolution Foundation and Rosenkranz Foundation to Fund Aging Science

United States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma

Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating the development of promising treatments to market announced the FDA authorization of a Phase II clinical trial to re-assess a targeted treatment in light of newly discovered pharmacogenomic predictor data in…

Read MoreUnited States Food and Drug Administration (FDA) Authorizes Phase 2 Study of DB107 In Promising Turn-Around of Targeted Treatment to Treat Newly Diagnosed High Grade Glioma

UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today announced the appointment of James Robinson, former President and Chief Executive Officer (CEO) of Urovant Sciences, to its…

Read MoreUroGen Pharma Announces the Appointment of James Robinson to its Board of Directors

NextGen Healthcare Chosen by Kymera Independent Physicians to Expand Access to Critical Hematology and Oncology Care in Rural Areas

NextGen Healthcare, Inc. (Nasdaq: NXGN), a leading provider of innovative, cloud-based healthcare technology solutions, today announced Kymera Independent Physicians multi-specialty group selected NextGen® Enterprise EHR – a powerful, all-encompassing electronic health record to expand access to care, while increasing clinical productivity, enriching patient experience, and…

Read MoreNextGen Healthcare Chosen by Kymera Independent Physicians to Expand Access to Critical Hematology and Oncology Care in Rural Areas

Siemens Healthineers launches Atellica CI Analyzer, compact testing system to tackle lab challenges

The newest addition to the Siemens Healthineers Atellica in vitro diagnostics portfolio, the Atellica CI Analyzer for immunoassay and clinical chemistry testing, has received FDA clearance and is now available in many of the world’s major markets. Labs operating at low to…

Read MoreSiemens Healthineers launches Atellica CI Analyzer, compact testing system to tackle lab challenges